This information was published on 2026-08-10T17:32:29 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2683150 |
| (220) |
04 Aug 2026
|
| (300) |
US, 06 Feb 2026, 99639512
|
| (511) (510) |
Class 5
Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, autoimmune diseases, solid organ transplant rejection, autoinflammatory diseases, blood diseases, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, Alzheimer’s disease, autism spectrum disorder, and musculoskeletal and skin diseases; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes. |
| (540) | JIBRELSO |
| (550) | Word |
| (730) |
Bristol-Myers Squibb Company
|
| (750) |
Spruson & Ferguson
|
Find out more about publications on the About page.